| Literature DB >> 29634432 |
Joel W Jones1, Shireen Usman1, Jacob New1,2, Andrew Holcomb1, Sumedha Gunewardena3, Ossama Tawfik4, Larry Hoover1, Daniel Bruegger1, Sufi Mary Thomas1,2,5.
Abstract
Juvenile nasopharyngeal angiofibroma (JNA) is a highly vascularized and locally aggressive tumor that typically presents in adolescent males. The molecular biology of this tumor remains understudied. We sought to identify differentially expressed genes in the JNA transcriptome through messenger RNA sequencing of primary fibroblasts from 2 tumor explants and tonsil tissue from tumor-free subjects. In total, 1088 significant, differentially expressed genes were identified with 749 upregulated and 339 downregulated. Pathway analysis identified a number of activated signaling pathways, most notably, the vascular endothelial growth factor (VEGF) pathway (adjusted overlap P = .03). VEGF-A showed a 4.4-fold upregulation in JNA samples. In addition, the angiogenic receptor, fibroblast growth factor receptor 2 (FGFR2), was not present in tumor-free samples but increased in JNA. We validate these findings with immunohistochemistry, demonstrating upregulation of VEGF and FGFR2 in patient sections. Inhibition of the VEGF or FGFR signaling axes may have therapeutic potential in the treatment of JNA.Entities:
Keywords: RNA sequencing; juvenile nasopharyngeal angiofibroma; transcriptome; vascular endothelial growth factor
Mesh:
Substances:
Year: 2018 PMID: 29634432 PMCID: PMC7147957 DOI: 10.1177/0194599818769879
Source DB: PubMed Journal: Otolaryngol Head Neck Surg ISSN: 0194-5998 Impact factor: 3.497